Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older
- People being treated for any type of cancer at the Montpellier Cancer Institute that requires chemotherapy
- People experiencing significant nerve pain, defined by a specific clinical scoring tool called the DN4 reaching a score of 4 or higher (confirm with trial site)
- People who have had nerve pain for at least 3 months after finishing adjuvant or neo-adjuvant chemotherapy
- Women who could become pregnant must have a negative pregnancy urine test taken within 7 days before starting the study treatment
- Women of childbearing potential must be using effective contraception
- People who have signed an informed consent form before any study procedures begin
- People enrolled in the French social security system
- People sufficiently fluent in French to complete questionnaires, as assessed by the investigator
Who may not be able to join:
- People unable to travel to the Montpellier Cancer Institute twice a week
- People unable to sit for a 30-minute period
- People who have an open wound or ulcer on the area of the body to be treated
- People whose nerve pain is caused by something other than chemotherapy (note: diabetes without nerve damage is not automatically excluded — confirm with trial site)
- People with an uncontrolled psychiatric illness or significant cognitive difficulties that could interfere with assessments, as judged by the investigator
- People whose life expectancy is estimated to be less than 3 months
- People already using another non-drug therapy or complementary treatment for nerve pain during the study
- People who have been treated with capsaicin (a pain relief treatment) within the past 3 months
- People with a pacemaker
- People with epilepsy
- People taking medications that cause sensitivity to light, or who have a medical condition that causes light sensitivity (such as lupus)
- Women who are pregnant or breastfeeding
- People who have a primary tumour or metastases in the hands and/or feet (the areas to be treated)
- People with a pre-existing eye condition (such as maculopathy, glaucoma, cataracts, or retinal lesions) or a family history of eye disease
- People who have previously received photobiomodulation treatment on the area to be treated
- People currently participating in another clinical study where the main focus is nerve pain or chemotherapy-related nerve damage
- People with a tattoo on the area of the body to be treated
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Estelle GUERDOUX, PHD, INSTITUT REGIONAL DU CANCER DE MONTPELLIER
Phone: 0467613102
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Evaluation of the efficacy of photobiomodulation on neuropathic pain in a experimental group and evaluate the placebo effect in a controlled group
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.